高影响力期刊心血管试验中非劣效界值超过优效性试验的死亡率效应估计
该研究系统检索2015年1月至2020年7月高影响力期刊中主要结局涉及死亡率且具统计学显著性的心血管试验,共纳入65项(39项非劣效、26项优效)。非劣效界值范围为风险差0.54%至10%,优效性试验的效应估计中位风险差为2.1%(四分位距1.5-4.9),28项(71.8%)非劣效试验的界值大于2.1%,32项(82.1%)大于1.5%。作者认为临床医生和指南制定组应关注研究结果而非作者的非劣效界值。
要点
- 非劣效界值范围为风险差0.54%至10%,跨度很大。
- 优效性试验中位风险差2.1%(四分位距1.5-4.9)。
- 28项(71.8%)非劣效试验界值大于2.1%,32项(82.1%)大于1.5%。
核心结论
- 非劣效界值范围非常宽泛,且多数超过多数人认为重要的死亡率降低阈值,提示临床医生和指南制定组应关注研究结果而非作者的非劣效界值。
研究设计与样本
- 系统检索PubMed、Embase和MEDLINE数据库(2015年1月至2020年7月),纳入高影响力期刊中主要结局涉及死亡率且具统计学显著性的心血管试验,共65项(39项非劣效、26项优效)。
主要发现
- 非劣效界值范围为风险差0.54%至10%。
- 优效性试验的效应估计中位风险差为2.1%(四分位距1.5-4.9)。
- 28项(71.8%)非劣效试验的界值大于2.1%,32项(82.1%)大于1.5%。
临床怎么用
- 作者认为临床医生和指南制定组应关注研究结果,对作者的非劣效界值关注较少。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine, in a sample of noninferiority trials, the noninferiority margins (NIMs) and their relation to effect estimates in superiority trials, the rationale being that in general NIMs should be no larger than effects declared important in superiority trials. STUDY DESIGN AND SETTING: To identify cardiovascular trials published in high-impact journals with a statistically significant primary outcome involving mortality, we systematically searched PubMed, Embase, and MEDLINE databases (January 2015-July 2020). We documented the NIMs and determined the proportion of trials with NIMs larger than the median effect estimates across superiority trials. RESULTS: From 1,477 screened titles, 65 (39 noninferiority, 26 superiority) trials proved eligible. The NIMs ranged from risk difference of 0.54-10%. The effect estimate across superiority trials was a median risk difference of 2.1% (interquartile range 1.5-4.9); the NIM was larger than 2.1% in 28 (71.8%) noninferiority trials and larger than 1.5%, which was the lower bound of the interquartile range in 32 (82.1%) noninferiority trials. CONCLUSION: The very wide range of noninferiority margins and the proportion above a threshold that most would consider an important mortality reduction suggest that clinicians and guideline panels should focus on study results, paying little attention to authors' noninferiority margins.
引用
- Ofori S, Cafaro T, Devereaux PJ, et al. Noninferiority margins exceed superiority effect estimates for mortality in cardiovascular trials in high-impact journals. J Clin Epidemiol. 2023. PMID: 37421996. doi:10.1016/j.jclinepi.2023.06.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。